Company intelligence / Profile preview

Chemokine Therapeutics Corp.

Vancouver, British Columbia, Canadapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Chemokine Therapeutics was a product-focused biotechnology company developing peptide-based drugs targeting chemokines and their receptors for cancer, blood disorders, and vascular diseases. Lead clinical candidates included CTCE‑9908 for cancer and CTCE‑0214 for neutropenia/stem cell mobilization. Clinical trials showed safety/tolerability in early phases but the company ceased operations after financial difficulties in 2008; no active development is reported since then.[5][9]

Therapeutic areas: OncologyCardiovascularNeurologyHematology
Modalities: Peptide-based drugs[1]Small molecules (inferred from chemokine/CXCR4 modulator focus)[4]
Industry: Biotech

Drug pipeline

3 assets

CTCE-9908

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Chemokine Therapeutics Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chemokine Therapeutics Corp..

Explore the full profile